COVID-19 Information for Cancer Researchers
COVID-19 Updates from NCI
Stay up to date with how NCI is adapting to the extraordinary circumstances imposed on the cancer community by COVID-19.
During the COVID-19 pandemic, NCI is continuing to advance cancer research while using its unique resources to help in the response to the pandemic.
Much of NCI's COVID-19 research will be done at the NCI-sponsored Frederick National Laboratory for Cancer Research in collaboration with other agencies, academic institutions, and research organizations. NCI is also funding extramural research on COVID-19.
On this page, you will find links to resources and guidance for extramural and intramural researchers and information about NCI's research related to COVID-19.
Information to help you talk to patients about COVID-19 clinical trials and studies and donating blood or plasma.
NCI COVID-19 Research
There is a lot to learn about how COVID-19 affects people, including those with cancer, and how to treat the disease. NCI is mobilizing its scientific experts and cutting-edge resources to conduct research on COVID-19.
List of ongoing clinical trials for coronavirus disease 2019 (COVID-19) supported by the National Cancer Institute. Some trials may be specifically for people with cancer who also have coronavirus disease.
Resources for COVID-19 Research
This pool of plasma from four donors with antibodies to the SARS-CoV-2 spike and nucleocapsid proteins is available by request to labs conducting COVID-19 antibody testing to enhance cross-study comparisons. The standard was developed by the Frederick National Laboratory for Cancer Research’s Serology Lab and will be used by the NCI Serological Sciences Network (SeroNet) and other scientists conducting COVID-19-related serology research.
SeroNet investigators have created guidance documents for researchers conducting studies on the immune response to vaccines to encourage harmonization across studies and to allow for cross-study comparisons. The available documents include study design templates, standard operating procedures, and common data elements.
Guidance for Extramural Researchers
Answers to key questions grantees may have about NCI funding notices for COVID-19, including what is in the scope of a parent grant, how NCI will evaluate the feasibility of proposed projects, and the anticipated timeframe for funding decisions.
NCI is providing funding for research on COVID-19 and revising some existing grants and cooperative agreements to make funds available to help address the public health crisis.
Current Guide Notices, Funding Opportunities, FAQs, and the latest information for NIH researchers on proposal submission, award management, human subjects and clinical trials, animal welfare, and peer review.
Answers to inquiries about policies and programs affecting the NIH grants process during the COVID-19 pandemic.
Guidance for Clinical Trial Investigators
Guidance from NCI and the NCI Central Institutional Review Board (CIRB) for investigators of CIRB-approved clinical trials, CTEP-supported clinical trials networks and consortia, and NCI Community Oncology Research Program (NCORP) Research Bases managing trial participants during the COVID-19 public health emergency.
Guidance from the Food and Drug Administration for industry, investigators, and institutional review boards.
Guidance for Intramural Researchers
A collection of information for NIH staff concerning laboratory and clinical operations, as well as links to resources for trainees and the broader scientific staff.